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Extensive vascular remodeling causing pulmonary hypertension (PH) represents a major
cause of mortality in patients with congenital diaphragmatic hernia (CDH). The chemokine
monocyte chemoattractant protein-1 (MCP-1) is a biomarker for the severity of PH and its
activation is accompanied by pulmonary influx of monocytes and extensive vascular remod-
eling. MCP-1 activation can be reversed by application of rosiglitazone (thiazolidinedione).
We performed this study to evaluate the role of MCP-1 for the pathogenesis of PH in experi-
mental CDH. We hypothesized that vascular remodeling and MCP-1 activation is accompa-
nied by pulmonary influx of fetal monocytes and can be attenuated by prenatal treatment
with rosiglitazone.
Methods
In a first set of experiments pregnant rats were treated with either nitrofen or vehicle on ges-
tational day 9 (D9). Fetal lungs were harvested on D21 and divided into CDH and control.
Quantitative real-time polymerase chain reaction, Western blot (WB), and immunohis-
tochemistry (IHC) were used to evaluate MCP-1 expression, activation, and localization.
Quantification and localization of pulmonary monocytes/macrophages were carried out by
IHC.
In a second set of experiments nitrofen-exposed dams were randomly assigned to prena-
tal treatment with rosiglitazone or placebo on D18+D19. Fetal lungs were harvested on D21,
divided into control, CDH+rosiglitazone, and CDH+placebo and evaluated by WB as well as
IHC.
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Results
Increased thickness of pulmonary arteries of CDH fetuses was accompanied by increased
systemic and perivascular MCP-1 protein expression and significantly higher amounts of
pulmonary monocytes/macrophages compared to controls (p<0.01). These effects were
reversed by prenatal treatment with rosiglitazone (p<0.01 vs. CDH+P; control).
Conclusion
Prenatal treatment with rosiglitazone has the potential to attenuate activation of pulmonary
MCP-1, pulmonary monocyte influx, and vascular remodeling in experimental CDH. These
results provide a basis for future research on prenatal immunomodulation as a novel treat-
ment strategy to decrease secondary effects of PH in CDH.
Introduction
The mortality of neonates with congenital diaphragmatic hernia (CDH) remains high despite
recent advances in intensive care including extracorporeal membrane oxygenation, nitric
oxide and alternative treatment strategies with sildenafil, bosentan and prostacyclins [1–5].
Persistent pulmonary hypertension (PH)–a result of perinatal vascular remodeling–is one of
the main contributors to mortality in CDH [6]. To evaluate alternative treatment strategies,
several groups investigated vascular changes in CDH lungs [6]. Although various pathome-
chanisms have been suggested, the molecular background of extensive vascular remodeling in
CDH leading to PH remains elusive.
Monocyte chemoattractant protein-1 (MCP-1) is a powerful monocyte chemoattractant
that has been found to be markedly increased in patients with PH and has therefore been sug-
gested as a biomarker for the severity of PH [7,8]. MCP-1 activation and the subsequent pro-
inflammatory phenotype can be dampened by application of the thiazolidinedione rosiglita-
zone, which has originally been developed as an insulin-sensitizer for the treatment of type 2
diabetes [9]. Due to its anti-inflammatory properties, rosiglitazone has been shown to inhibit
MCP-1 expression, subsequent monocyte activation and ultimately to attenuate experimental
pulmonary hypertension in rodent models [9–14].
To date, the effects of increased systemic MCP-1 expression in CDH remain unclear. Fur-
thermore, protein localization and the biological activity of the chemoattractant have not been
determined.
In this study we hypothesized that MCP-1 activation is accompanied by increased pulmo-
nary influx of monocytes/macrophages, leading to vascular remodeling and contributing to
the development of PH in a well-established rat model of CDH. We further aimed to investi-
gate if prenatal attenuation of MCP-1 expression decreases pulmonary monocyte influx in
CDH and therefore might represent a potential therapeutic target for the treatment of PH in
CDH.
Methods
Animals and drug administration
Pathogen-free Sprague-Dawley rats (Harlan UK Ltd., Bicester, UK) were kept in a tempera-
ture-controlled environment with a 12h-light period and water and food ad libitum. In a first
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set of experiments, adult Sprague-Dawley rats were naturally mated overnight, separated and
checked for plugging. Presence of spermatozoids in the vaginal smear was considered as proof
of pregnancy and pregnant females were randomly divided into 2 groups (“control” and
“CDH”). On gestational day 9 (D9), 100 mg of nitrofen (2,4-dichloro-p-nitrophenyl ether,
WAKO Chemicals, Osaka, Japan) dissolved in 1 ml olive oil was administered intragastrically
to animals of the CDH group, as previously described [15]. Animals assigned to the control
group received vehicle only. Gestational day 21 (D21) was selected as endpoint and fetuses
were delivered via cesarean section. Therefore, dams were anesthetized in an induction cham-
ber using 2% isoflurane (Piramal Healthcare, Morpeth, UK) and maintained at 1% for delivery.
Fetuses were euthanatized by decapitation and inspected by laparatomy for CDH. Only fetuses
with left-sided CDH were included in the following analyses. Fetal serum was obtained by
decapitation and exsanguination. After centrifugation (2000G for 5 min), supernatant was col-
lected, snap frozen and stored at -80˚C for further analysis. Left lungs from animals with CDH
(n = 32) as well as lungs from controls (n = 32) were dissected and either snap-frozen (and
stored native at -80˚C) for RNA isolation and protein extraction or fixed in formalin for
immunohistochemistry.
In a second set of experiments, timed-pregnant Sprague-Dawley rats were randomly
assigned to one of three groups [control, CDH+Placebo (CDH+P) or CDH+Rosiglitazone
(CDH+R)]. On D9, animals of the control group were administered vehicle only, whereas ani-
mals of the groups CDH+P and CDH+R received nitrofen as described above. Additionally,
on D18 and D19, 3 mg/kg bodyweight of the thiazolidinedione rosiglitazone (Cayman Chemi-
cal, Ann Harbor, MI, USA) was administered intraperitoneally as single shot (in 100μL cotton-
seed oil + 400μL PBS) under isoflurane anesthesia to animals of the CDH+R group, while
animals of the CDH+P group received diluent alone. The time point and dosage of prenatal
rosiglitazone treatment were adopted from the previously described prenatal application of
rosiglitazone in a model of hyperoxia-induced neonatal rat lung injury [11]. According to
experimental set 1, dams were anesthetized on D21 and fetuses were delivered and processed
for further examination as described (control: n = 15; CDH+P: n = 14; CDH+R: n = 16). All
animal procedures were performed in accordance to the guidelines for management and wel-
fare of laboratory animals and were approved by the Department of Health and Children (Ref:
B100/4378) under the Cruelty to Animals Act, 1876, as amended by the European Council
Directive of 2010 (2010/63/EU).
RNA isolation and quantitative real-time polymerase chain reaction
(qRT-PCR)
After dissection, total RNA was isolated from left fetal lungs using the acid guanidium thio-
cyte-phenol-chloroform extraction method with TRIzol reagent (Invitrogen, Carlsbad, CA,
USA) following the manufacturer’s protocol. RNA quantification was performed using a
NanoDrop spectrophotometer (NanoDrop ND-1000 UV-Vis Spectrophotometer, Wilming-
ton, DE, USA). Subsequently, RNA was stored at -20˚C. For qRT-PCR, 1 μg of total RNA was
reverse-transcribed into single stranded cDNA at 85˚C for 3 min (denaturation), at 44˚C for
60 min (annealing) and at 92˚C for 10 min (reverse transcriptase inactivation) using the Tran-
scriptor High Fidelity cDNA Synthesis Kit (Roche Diagnostics, West Sussex, UK). qRT-PCR
analysis was performed in a total reaction mix of 20 μl per well using a LightCycler 480 SYBR
Green I Master (Roche Diagnostic, Mannheim, Germany). Primers are listed in Table 1. Each
reaction was run in duplicate for each sample and primer pair under the following conditions:
denaturation at 95˚C for 5 min, 45 cycles of denaturation (95˚C, 10 sec), annealing (60˚C 15
sec) and elongation (72˚C 10 sec). Expression levels of MCP-1 were determined using a
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LightCycler 480 (Roche Diagnostics, Mannheim, Germany) and normalized against the β-
actin gene expression in each sample (ΔΔCT-method).
Western blot
Western blotting (WB) from fresh frozen whole lungs was performed as previously described
[16,17]. In brief, defrosted lungs were quickly homogenized and proteins were isolated in lysis
buffer (25 mM Tris-HCL, 50 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 1% NP-40, 10% glycerol
and 1% protease inhibitor cocktail). After determination of total protein concentration, equal
amounts of protein (200 μg) were denatured in Laemmli sample buffer (Sigma-Aldrich Ireland
Ltd., Wicklow, Ireland) and protein separation was performed by gel electrophoresis using
precast 10% SDS polyacrylamide gels (NuPage Novex Bis-Tris gels, Invitrogen, Carlsbad, CA,
USA) in NuPage MES SDS running buffer (Invitrogen, Carlsbad, CA, USA). Proteins were
then transferred to 0.45 μm nitrocellulose and blots were blocked overnight in 3% BSA in
PBST. Determination of MCP-1 was carried out using a primary antibody against MCP-1
(goat polyclonal, sc-1785; dilution 1:500, Santa Cruz Biotechnology Inc, Santa Cruz, CA,
USA). After overnight incubation at 4˚C (shaking), blots were extensively washed in PBST for
4 h, incubated with the secondary antibody, and washed again. Finally, the PIERCE chemilu-
minescence kit (Thermo Fisher Scientific, Dublin, Ireland) was used for detection. Equal load-
ing of electrophoresis gels was controlled by Bradford assay (200 μg total protein), confirmed
by coomassie staining of the gel and β-actin staining of the stripped membranes (S1 and S2
Figs). For semiquantitative analysis, protein band intensities were normalized for loading con-
trol using β-actin (ab8227, 1:5000, Abcam plc, Cambridge, UK) of stripped membranes.
Enzyme-linked immunosorbent assay
Fetal serum was evaluated for MCP-1 concentration using the Invitrogen MCP-1 Rat Instant
Enzyme-linked immunosorbent assay (ELISA) Kit (BMS631INST, Thermo Fisher Scientific,
Dublin, Ireland) according to the manufacturer’s instructions. The results were measured at
450 nm with a Bio Tek SynergyT Mx microplate reader (Bio Tek, Winooski, VT, USA) imme-
diately after adding the stop solution. Experiments were carried out in duplicate for each data
point.
Immunohistochemistry
For immunohistochemistry (IHC), formalin fixed left lungs were washed overnight in PBS at
4˚C, embedded in OCT Mounting tissue (VWR International, Leuven, Belgium) and stored at
-80˚C. Transversal sections of 10 μm thickness were cut from frozen blocks and placed on
SuperFrost Plus slides (VWR International, Leuven, Belgium). Sections were then washed in
PBS and underwent cell membrane permeabilization for 20 min at room temperature using
1% Triton X-100 in PBS. After washing, sections were preincubated with blocking solution for
30 min (10% bovine serum, 0.3 M glycine) followed by incubation with primary antibodies
against MCP-1 (goat polyclonal, sc-1785; dilution 1:100 in PBST, Santa Cruz Biotechnology
Table 1. Gene-specific primer sequences.
Gene Primer sequence Product size (bp)
MCP-1 fw CCAGAAACCAGCCAACTCTC 70
MCP-1 rev GCGTGACAGAGACCTGCATA
β-actin fw TTGCTGACAGGATGCAGAAG 108
β-actin rev TAGAGCCACCAATCCACACA
https://doi.org/10.1371/journal.pone.0206975.t001
Prenatal treatment with rosiglitazone in congenital diaphragmatic hernia
PLOS ONE | https://doi.org/10.1371/journal.pone.0206975 November 12, 2018 4 / 14
Inc, Santa Cruz, CA, USA) and smooth muscle actin (SMA, mouse monoclonal, M0851, 1:200
dilution in PBST, DAKO Diagnostics Ireland Ltd., Dublin, Ireland) overnight at 4˚C. Corre-
sponding secondary antibodies (donkey anti-goat Alexa 555 –A21432, goat anti-mouse Alexa
488 –A11029, Invitrogen, USA) were applied after washing at room temperature for 30 min.
Again, sections were washed, counterstained with DAPI (1:1000 in PBST, Roche, Mannheim,
Germany), mounted and coverslipped with Sigma Mounting medium (Sigma Aldrich, USA).
For analysis, a Zeiss LSM 700 confocal microscope (Carl Zeiss MicroImaging, Jena, Germany)
was used.
For immunohistochemistry of ED1+ cells (monocytes/macrophages), dewaxed paraffin sec-
tions of lungs were used. Detection of macrophages was performed with a mouse monoclonal
antibody to CD68 (anti-rat CD68, clone ED1, MCA 341 R, AbD Serotec, Bio-Rad, Hercules,
CA 94547, USA). Slides were incubated with the primary antibody for 1 h at 21˚C. As second-
ary antibody, a biotin-SP-conjugated AffiniPure goat-anti-mouse (Jackson Immunoresearch,
West Grove, PA, USA, 115-065-166) was applied for an incubation time of 30 min at 21˚C.
Immunostaining was done with a routine method using alkaline phosphatase streptavidin-bio-
tin (Vector Laboratories Inc., Burlingame, CA, USA, S-5100) and as chromogen Fast Red (Fast
Red substrate pack, BioGenex, Fremont, CA, USA, HK182-5K). The slides were finally coun-
terstained with Mayer’s hematoxylin (Linaris Biologische Produkte GmbH, Wertheim-Bettin-
gen, Germany, EGH3411). For evaluation of the number of monocytes/macrophages, ED-1
stained sections were blinded and randomized. Perivascular ED1+ monocytes/macrophages
were counted in four representative, non-overlapping high-power fields per section by two
independent investigators.
Quantification of pulmonary vascular smooth muscle layer thickness and
MCP- 1 staining intensity
Based on immunohistochemical SMA staining, a semi quantitative analysis of the pulmonary
vascular smooth muscle layer thickness was performed. Therefore, the thickness of SMA posi-
tive pulmonary vessels was measured at three positions using the distance tool of ZEN 2.3 Soft-
ware (Zeiss, Jena, Germany) in 6 representative microscopic photographs per group.
Accordingly, perivascular MCP-1 intensity was assessed using Zen Software. Comparability
was enabled on the basis of a standardized staining and scanning protocol including identical
exposure times as well as normalization against the corresponding negative controls for each
microscopic photograph.
Statistical analysis
Data are represented as mean ± standard deviation (SD). After testing for normal distribution
by Kolmogorov-Smirnov, differences between groups were evaluated by t-test and ANOVA
with posthoc Tukey´s multiple comparisons test for parametric samples. Statistics were per-
formed by OriginPro 8.1 (Additive GmbH, Friedrichsdorf, Germany), GraphPad Prism 7.04
(La Jolla, CA, USA) and Statistical Package for the Social Science (V24). Significance level was
set as p<0.05.
Results
MCP-1 mRNA and protein expression is increased in nitrofen-induced
CDH
Nitrofen-exposed lung tissue revealed significantly increased MCP-1 mRNA levels compared
to control lung as shown by qRT-PCR (Fig 1A; 4.0 fold increase over control; p = 0.04). ELISA
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(Fig 1B; 1.3 fold increase over control; p = 0.01) revealed an increased systemic MCP-1 serum
concentration and WB (Fig 1C; 5.2 fold increase over control; p = 0.004) confirmed that the
increased MCP-1 transcripts in samples of CDH lungs resulted in significantly increased
MCP-1 protein levels compared to control lungs (S1 Fig). Additionally, a generally strong
immunoreactivity of MCP-1 in CDH lung sections indicated elevated MCP-1 levels (Fig 2).
Vascular remodeling in nitrofen-induced CDH is accompanied by
increased pulmonary MCP-1 protein expression and pulmonary monocyte/
macrophage influx
Medial and adventitial thickness of small and large pulmonary vessels was markedly increased
in CDH lungs compared to controls. The observed vascular remodeling was accompanied by a
strong perivascular immunoreaction of MCP-1 around small as well as large pulmonary ves-
sels in CDH lungs, as shown by SMA and MCP-1 immunostaining (Fig 2).
To assess the effect of different MCP-1 levels on monocytes/macrophages, immunohis-
tochemistry and quantification of ED1-positive cells on immunostained sections were per-
formed. Both procedures demonstrated significantly increased levels of monocytes/
macrophages in lungs of nitrofen-exposed animals (Fig 3).
Effects can be reversed by prenatal application of rosiglitazone
The effect of prenatally administered rosiglitazone was investigated by double immunostaining
(SMA, MCP-1) as well as WB (MCP-1) as described for experimental set 1. SMA as well as
MCP-1 were observed in an alleviated pattern, which was similar to those of control sections
after prenatal treatment with rosiglitazone in nitrofen-exposed dams.
Significantly increased thickness of pulmonary vessels of all sizes was confirmed in CDH
lung tissue from rats treated with placebo only (CDH+P, p = 0.001) and could not be identified
in fetuses prenatally treated with rosiglitazone on D18 and D19 (CDH+R, Fig 4, S3A Fig).
Fig 1. MCP-1 mRNA and protein expression. MCP-1 mRNA expression levels were significantly increased in nitrofen-exposed lungs compared to
normal tissue as shown by qRT-PCR (A: 4.0 fold increase over control, p = 0.04). Increased systemic MCP-1 serum levels were observed in the CDH
group compared to control by ELISA (B, 1.3 fold increase over control, p = 0.01). Western blotting analyses confirmed these findings by revealing
significantly increased MCP-1 protein levels in CDH lung tissue (C, 5.2 fold increase over control, p = 0.004). Statistical analysis by Student´s t-test,
�p<0.05, ��p<0.01.
https://doi.org/10.1371/journal.pone.0206975.g001
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Fig 2. Pulmonary MCP-1 expression. Immunofluorescence evaluation of MCP-1 and SMA demonstrated markedly increased medial and
adventitial thickness of small (A, C) and large (B, D) pulmonary vessels in CDH lung tissue compared to controls. Additionally, immunoreaction of
MCP-1 and SMA was augmented around pulmonary arteries in CDH lung tissue (C, D). Scale bar 30 μm.
https://doi.org/10.1371/journal.pone.0206975.g002
Fig 3. Pulmonary monocytes/macrophages. Quantification of ED1-positive cells (A) revealed significantly increased numbers of monocytes/
macrophages in CDH lungs. Immunofluorescence showed an accumulation of ED1-positve cells around pulmonary vessels in nitrofen-exposed CDH
lungs (C) compared to controls (B). Statistical analysis by Student´s t-test, �p<0.05, ��p<0.01, p���<0.001, Scale bar 50 μm.
https://doi.org/10.1371/journal.pone.0206975.g003
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Overall as well as perivascular MCP-1 protein expression were significantly decreased in
lung tissue of rosiglitazone-treated animals with CDH compared to lungs of placebo-treated
CDH animals as shown by western blotting (Fig 5) and immunohistochemistry (S3A and S3B
Fig, p = 0.018).
Fig 4. Pulmonary MCP-1 expression after prenatal treatment with rosiglitazone. After prenatal treatment with rosiglitazone (CDH+R; E, F), no
increase in thickness of pulmonary vessels as well as of MCP-1 and SMA immunoreactivity could be observed in CDH lungs compared to controls
(control; A, B). Treatment with placebo only resulted in the typical medial and adventitial changes as well as increased immunoreactivity of MCP-1
and SMA in the pulmonary vasculature of CDH fetuses (CDH+P; C, D). Scale bar 30 μm.
https://doi.org/10.1371/journal.pone.0206975.g004
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ED1 immunohistochemistry revealed significantly reduced numbers of pulmonary mono-
cytes/macrophages in sections of rosiglitazone-treated animals compared to placebo-treated
CDH animals (19.8±4 vs. 26.4±-5.0, p = 0.006; Fig 5).
Discussion
PH is one of the key determinants of outcome in patients with CDH. It is characterized by
increased pressure in the pulmonary artery circulation resulting from a significant vascular
remodeling of small and large pulmonary vessels [6]. Histologically, a medial and adventitial
thickening of pulmonary arteries of all sizes has been described in human specimen and can
be reliably reproduced in the nitrofen CDH model [18–22]. In the present study, these specific
features of vascular remodeling have been confirmed: We observed a relevant thickening of
pulmonary vessels with increased layers of vascular smooth muscle cells (SMCs) in fetal rat
lungs with CDH compared to controls. However, the molecular background of vascular
remodeling observed in nitrofen-induced CDH remains elusive.
Normal pulmonary vasculogenesis is dependent on a crucial balance between proliferation
and apoptosis of SMCs [23,24]. Besides its key function in regulation of the migration and
infiltration of monocytes/macrophages, the chemokine MCP-1 has recently been attributed an
important role as a potent inductor of SMC proliferation [25]. In this regard, increased MCP-1
levels have been shown to be associated with the development of severe PH due to increased
vascular remodeling in neonatal and preterm lungs of humans and in rodent models [8,13,26–
30]. However, the prenatal relevance of pulmonary MCP-1 expression especially in CDH has
not been investigated to date.
We previously reported on increased pulmonary MCP-1 mRNA expression in fetal lungs of
nitrofen-induced CDH rats [15]. In the present study, we proved that the increased pulmonary
MCP-1 mRNA transcripts observed in CDH were translated to the protein level. Increased
MCP-1 protein expression was predominantly localized perivascular, suggesting a possible
association of MCP-1 on the prenatal pulmonary vascular development. It remains unclear if
Fig 5. Pulmonary MCP-1 expression and monocytes/macrophages after prenatal treatment with rosiglitazone. MCP-1 protein levels were decreased in lungs of
CDH fetuses treated with rosiglitazone (CDH+R) compared to CDH fetuses exposed to placebo only (CDH+P), as demonstrated by western blotting. This was
accompanied by a significantly reduced number of pulmonary monocytes/macrophages, shown by ED1 immunohistochemistry. Scale bar 50 μm.
https://doi.org/10.1371/journal.pone.0206975.g005
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this observation represents the cause or the result of prenatal vascular remodeling in experi-
mental CDH.
MCP-1 is produced by alveolar epithelial, endothelial, SMCs, and monocytes/macrophages
after exposition with acute phase proteins, bacterial or viral products [26,31]. The activation of
perivascular monocytes/macrophages by increased MCP-1 expression has been shown to
result in endothelial dysfunction and SMC proliferation. Based on rodent and large animal
models, increased MCP-1 expression has been suggested to contribute to a pro-inflammatory
phenotype [10,25,32–34]. This pro-inflammatory phenotype is maintained due to aberrant cel-
lular cross-talk between mesenchymal cells and macrophages and subsequently promotes tran-
sition to chronic non-resolving inflammation and vascular remodeling [25].
To evaluate the impact of increased pulmonary MCP-1 expression in our model, we investi-
gated the respective target cells. In the present study, increased perivascular MCP-1 protein
expression was accompanied by significantly enhanced pulmonary infiltration of ED1-positive
monocytes/macrophages in fetal rat lungs with CDH compared to controls. This enhanced
perivascular monocyte/macrophage infiltration suggests a relevant impact of the observed
MCP-1 protein expression pattern in fetal CDH lungs, thus contributing to extensive vascular
remodeling by maintaining a pro-inflammatory phenotype.
Besides the induction of an anti-inflammatory signaling cascade, the transcription factor
peroxisome proliferator-activated receptor γ (PPARγ) has been attributed a key role in physio-
logical pulmonary angiogenesis during the late stages of fetal lung development together with
the bone morphogenetic protein receptor 2 (BMPR2) [9,11,16,35–37]. PPARγ/BMPR2 signal-
ing is essential for the modulation of differentiation, proliferation, and the fibrous matrix pro-
duction of both endothelial and SMCs by controlling an antiproliferative signaling pathway
[9,16,36]. Disruption of this signaling cascade has been shown to result in uncontrolled SMC
proliferation significantly contributing to PH in humans and experimental settings
[9,35,36,38]. In contrast, activation of the PPARγ/BMPR2 signaling pathway has been sug-
gested to prevent vascular remodeling ensuring a normal vasculogenesis [9,11,37]. MCP-1
expression and vascular remodeling can be inhibited by the PPARγ-agonist rosiglitazone (thia-
zolidinedione) [9,39]. However, prenatal effects of rosiglitazone on the pulmonary vasculature
of fetuses with CDH have not been evaluated to date. In the present study, we show for the
first time that prenatal application of rosiglitazone on D18 and D19 reduced MCP-1 expres-
sion, monocyte/macrophage infiltration and vascular remodeling in fetuses with CDH com-
pared to placebo-treated animals. These data clearly show that prenatal activation of the
PPARγ/BMPR2 signaling pathway attenuates the previously described features of vascular
remodeling in experimental CDH. We therefore suggest that modulation of this signaling cas-
cade represents a potential target for prenatal attenuation of PH in CDH.
Limitations of our study include the lack of data on postnatal outcome after prenatal treat-
ment with rosiglitazone. Survival studies of rats after nitrofen-induction of CDH do not meet
up-to-date ethical standards. Due to the severity of PH and hypertension in this animal model,
the majority of the neonatal rats die immediately after birth.
To evaluate the relevance of our findings regarding a translation from bench to bedside, the
next step will be to investigate whether the PPARγ/BMPR2 signaling is altered in human CDH
as well and may therefore have a significant impact on future treatment strategies.
Conclusions
Increased pulmonary MCP-1 expression in fetal rat lungs with CDH has a relevant impact on
prenatal pulmonary monocyte/macrophage infiltration and vascular remodeling. Prenatal
treatment with rosiglitazone has the potential to attenuate activation of pulmonary MCP-1,
Prenatal treatment with rosiglitazone in congenital diaphragmatic hernia
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pulmonary monocyte influx, and vascular remodeling in experimental CDH. These results
provide a basis for future research on prenatal immunomodulation as a novel treatment strat-
egy to decrease secondary effects of PH in CDH.
Supporting information
S1 Fig. Pulmonary MCP-1 protein expression. Western blotting result of experimental set 1
show an increased MCP-1 protein expression in CDH lung tissue compared to controls (A).
Equal loading of electrophoresis gels was controlled by Bradford assay and confirmed by beta-
actin staining of the stripped membranes (B).
(TIF)
S2 Fig. Pulmonary MCP-1 protein expression after treatment with rosiglitazone. Western
blotting result of experimental set 2 show an increased MCP-1 protein expression in CDH
lung tissue from rats treated with placebo (CDH+P) compared to controls and CDH lungs
from rosiglitazone-treated fetuses (CDH+R) (A, B). Equal loading of electrophoresis gels was
controlled by Bradford assay and confirmed by Coomassie staining of the gel (A1, B1).
(TIF)
S3 Fig. Vascular smooth muscle layer thickness and perivascular MCP-1 expression. (A)
The relative vascular smooth muscle layer thickness was significantly increased in CDH lung
tissue from rats treated with placebo only (CDH+P) compared to controls (p = 0.001) and
fetuses prenatally treated with rosiglitazone on D18 and D19 (CDH+R, p = 0.008).
(B) Perivascular MCP-1 protein expression was significantly decreased in lung tissue of rosigli-
tazone-treated animals with CDH (CDH+R, p = 0.018) compared to lungs of placebo-treated
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